Editorial commentaries
801 Deep brain stimulation ‘probably’ works on patients with tardive syndromes
C Zhang, B Sun

802 Still seeking the holy grail of outcome measures in inclusion body myositis
J-Y Hagel

804 Tumour necrosis factor inhibitor monotherapy for CNS neosarcoidosis
J M Celfiend

Cerebrovascular disease
805 Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants

Impact of mobile stroke units
K Fodorhody, F Arzoz, M Leoneiste, S Walter, J Q Groenwald, A Raggoes-Schulmer, T Borsch, J Costa

823 Lacunar stroke: mechanisms and therapeutic implications
S Yagi, E Ratz, D Yang, S Cutting, B Mac Geor, M SV Elkink, A de Havenon

Multiple sclerosis
831 Early factors associated with late conversion to multiple sclerosis in patients presenting with isolated myelitis
O C Murphy, I Mukhatesh, A Salazar-Camejo, C A Pardo, S D Newsome

839 Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up
L Hadar, K Chung, G Bird, A Eskahli, S Mangessas, F Peaks, C Tur, O Ciciretti, F Barkhof, D Ched

Cognitive neurology
847 The Impact of Traumatic Brain Injury on Neurocognitive Outcomes in Children: a Systematic Review and Meta-Analysis
M S L Goh, D S H Lux, J L Goh, R Sulthan, S S M Goh, J W Lee, S-L Chong

Neuroinflammation
890 TNF-a inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis
F Hilizian, A Matraoui, C Boutiere, A Rico, S Demontier, P Kerschen, T Sene, C Benoist-Kocher, C Gavassini, J Capron, A Mekine, J-P Comessarché, G Androulas, R Marignier, N Collongues, O Casez, C Codan, M Vaillant, G Mathieu, J Giron, J Pelletier, B Auroux, Under the aegis of the French Multiple Sclerosis Society

Spinal cord injury
863 Microstructural plasticity in nociceptive pathways after spinal cord injury
S P Khyathakakhy, M Azzario, J Rosner, V D Callison, C Bliaut, J Ashermer, N Weiskopf, K Wiesch, K Frisoni, G Ziegler, P Freund

Neurodegeneration
872 Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease

881 Early atypical signs and insulin hypometabolism predict survival in multiple system atrophy
S Gomadi, M Bouckhine, T Wijns, F Flachere, J-P Azulay, E Guesd, A Eusebio

Neuromuscular
854 Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis
G Sanghvi, B Yao, D Lum, I Skorupinska, L I Cermain, D Kozyn, M Panton, J Miller, C G Hanna, D Hilton-Jones, J Freedby, P M Machado

Disclaimer: The Editor of JNNP has been granted editorial freedom and JNNP is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. JNNP is primarily intended for healthcare professionals and its content is for information only. The Journal is not for sale and any reproduction by any means is strictly prohibited. BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage however arising from JNNP except for liability which cannot be legally excluded.

Copyright: © 2021 BMJ Publishing Group Ltd. All rights reserved; no part of this publication may be reproduced in any form without permission. JNNP is published by BMJ Publishing Group Ltd, typeset by Jern Press Ltd, London. Artwork and printing is in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11432, USA. Periodicals postage paid at Brooklyn, NY 11236. US Postmaster: Send address changes to Journal of Neurology Neurosurgery & Psychiatry, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11432, USA. Subscription records are maintained at BMJ House, Twickenham Square, WC1H 9JR London A4 Business Ltd is acting as our mailing agent.

Volume 92 Issue 8 | JNNP August 2021

Contents

Editorial commentaries
801 Deep brain stimulation ‘probably’ works on patients with tardive syndromes
C Zhang, B Sun

802 Still seeking the holy grail of outcome measures in inclusion body myositis
J-Y Hagel

804 Tumour necrosis factor inhibitor monotherapy for CNS neosarcoidosis
J M Celfiend

Cerebrovascular disease
805 Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants

Impact of mobile stroke units
K Fodorhody, F Arzoz, M Leoneiste, S Walter, J Q Groenwald, A Raggoes-Schulmer, T Borsch, J Costa

823 Lacunar stroke: mechanisms and therapeutic implications
S Yagi, E Ratz, D Yang, S Cutting, B Mac Geor, M SV Elkink, A de Havenon

Multiple sclerosis
831 Early factors associated with late conversion to multiple sclerosis in patients presenting with isolated myelitis
O C Murphy, I Mukhatesh, A Salazar-Camejo, C A Pardo, S D Newsome

839 Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up
L Hadar, K Chung, G Bird, A Eskahli, S Mangessas, F Peaks, C Tur, O Ciciretti, F Barkhof, D Ched

Cognitive neurology
847 The Impact of Traumatic Brain Injury on Neurocognitive Outcomes in Children: a Systematic Review and Meta-Analysis
M S L Goh, D S H Lux, J L Goh, R Sulthan, S S M Goh, J W Lee, S-L Chong

Neuroinflammation
890 TNF-a inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis
F Hilizian, A Matraoui, C Boutiere, A Rico, S Demontier, P Kerschen, T Sene, C Benoist-Kocher, C Gavassini, J Capron, A Mekine, J-P Comessarché, G Androulas, R Marignier, N Collongues, O Casez, C Codan, M Vaillant, G Mathieu, J Giron, J Pelletier, B Auroux, Under the aegis of the French Multiple Sclerosis Society

Spinal cord injury
863 Microstructural plasticity in nociceptive pathways after spinal cord injury
S P Khyathakakhy, M Azzario, J Rosner, V D Callison, C Bliaut, J Ashermer, N Weiskopf, K Wiesch, K Frisoni, G Ziegler, P Freund

Neurodegeneration
872 Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease

881 Early atypical signs and insulin hypometabolism predict survival in multiple system atrophy
S Gomadi, M Bouckhine, T Wijns, F Flachere, J-P Azulay, E Guesd, A Eusebio

Neuromuscular
854 Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis
G Sanghvi, B Yao, D Lum, I Skorupinska, L I Cermain, D Kozyn, M Panton, J Miller, C G Hanna, D Hilton-Jones, J Freedby, P M Machado

This article has been chosen by the Editor to be of special interest and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme. See http://authors.bmj.com/open-access/

The article is part of the Impact Commentaries series

MORE CONTENTS ▶
Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management